SCHEMBL4723855

SCHEMBL4723855

CCCN(C)C1[C]Oc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SIGMAR1 Q99720 2/20 0.40
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
USP2 O75604 1/20 0.33
KCNE1 P15382 1/20 0.33
KCNQ1 P51787 1/20 0.33
SLC22A2 O15244 1/20 0.33
SLC22A3 O75751 1/20 0.33
TP53 P04637 1/20 0.32
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720879 0.91 KMT2A (0.36) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4722635 0.87 MEN1 (0.38) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4722732 0.85 MEN1 (0.42) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4722833 0.84 MEN1 (0.39) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4723614 0.84 MEN1 (0.41) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4724912 0.80 KMT2A (0.38) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4721713 0.79 KMT2A (0.37) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4723880 0.79 GPR3 (0.38) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4723731 0.78 KMT2A (0.36) MEN1KMT2ATSHRSMN1; SMN2NPSR1
SCHEMBL4765769 0.78 MEN1 (0.39) MEN1KMT2ATSHRSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MEN1 4451/4885KMT2A 3345/4885TSHR 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.